Scientific Publications

New aspects in the pathophysiology of preeclampsia

J.M. Davison
V. Homuth
A. Jeyabalan
K.P. Conrad
S.A. Karumanchi
S. Quaggin
R. Dechend
F.C. Luft

Update on the toxicology and pharmacology of rDSPA alpha 1 (Bat-PA) in animals and humans

D.C. Gulba
M. Praus
R. Dechend
S. Hauck
M. Mahler
R. Zitvz
B. Baldus
W. Mueller
R. Dietz

AT1 receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor

R. Dechend
V. Homuth
G. Wallukat
J. Kreuzer
J.K. Park
J. Theuer
A. Juepner
D.C. Gulba
N. Mackman
H. Haller
F.C. Luft

July 01, 2000 / Am J Pathol

Angiotensin II (AT1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy

D.N. Mueller
E.M.A. Mervaala
R. Dechend
A. Fiebeler
J.K. Park
F. Schmidt
J. Theuer
V. Breu
N. Mackman
T. Luther
W. Schneider
D. Gulba
D. Ganten
H. Haller
F.C. Luft

Translational control of C/EBP alpha and C/EBP beta isoform expression

C.F. Calkhoven
C. Mueller
A. Leutz

Antihypertensive Behandlung. Bei Risikopatienten von Anfang an fix kombinieren [Fixed-dose combinations in antihypertensive treatment: is it necessary to examine the effectiveness of each component?]

R. Dechend
W. Derer
D.N. Mueller

Crosstalk between C/EBPbeta phosphorylation, arginine methylation, and SWI/SNF/Mediator implies an indexing transcription factor code

E. Kowenz-Leutz
O. Pless
G. Dittmar
M. Knoblich
A. Leutz

Increased angiotensin II in the mesometrial triangle of a transgenic rat model of preeclampsia

K.B. Brosnihan
L. Hering
R. Dechend
M.C. Chappell
F. Herse

Vitronectin concentrations predict risk in patients undergoing coronary stenting

W. Derer
E.S. Barnathan
E. Safak
P. Agarwal
H. Heidecke
M. Moeckel
M. Gross
C. Oezcelik
R. Dietz
R. Dechend

Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1

J. Lausen
O. Pless
F. Leonard
O.N. Kuvardina-Bolling
B. Koch
A. Leutz